Runt-related transcription factor 2 (RUNX2) (RUNX2)

Runt-related transcription factor 2 (RUNX2), historically known as Core-binding factor alpha 1, is a master transcription factor of the RUNX family that plays an indispensable role in skeletal development and bone formation (MedlinePlus Genetics, 2017; PMC: 5937198). It serves as a crucial regulatory switch for the commitment of mesenchymal stem cells to the osteoblast lineage and governs the subsequent maturation of chondrocytes during endochondral ossification (NCBI Gene, 2025; Ma'ayan Lab). Pathologically, RUNX2 is implicated in a variety of diseases; loss-of-function mutations cause the skeletal disorder cleidocranial dysplasia, while its aberrant overexpression is associated with tumor progression and bone metastasis in breast, prostate, and lung cancers (PubMed: 32788656; MDPI, 2023). Due to its roles in promoting epithelial-mesenchymal transition and angiogenesis, RUNX2 has emerged as a promising therapeutic target, with experimental small molecules like CADD522 being developed to inhibit its DNA-binding activity and reduce tumor burden in preclinical models (PubMed: 29050333; Osteosarcoma Now, 2023). However, the therapeutic application of RUNX2 modulators must carefully balance antitumor efficacy with potential safety concerns regarding systemic bone homeostasis and normal skeletal integrity (MedlinePlus Genetics, 2017; PubMed: 32788656).

Other names

Core-binding factor alpha 1CBFA1Acute myeloid leukemia 3 proteinAML3Osteoblast-specific transcription factor 2OSF-2PEBP2-alpha ASL3-3 enhancer factor 1 subunit alphaRunt-related transcription factor 2

Inhibition of DNA binding and modulation of protein stability through post-translational modifications such as phosphorylation and acetylation